The above studies indicate that considering PD-1/PD-L1 antibodies as an adjuvant treatment scheme for AML can effectively enhance the sensitivity of cell therapy and chemotherapeutic agents, which is a promising combination-chemotherapy option. The gene discussed is PDCD1; the disease is acute myeloid leukemia.